Page 1015 - Basic _ Clinical Pharmacology ( PDFDrive )

CHAPTER 55 Immunopharmacology 1001

GENERIC NAME AVAILABLE AS GENERIC NAME AVAILABLE AS
Pegademase bovine Adagen Rilonacept Arcalyst
(bovine adenosine deaminase) Rituximab Rituxan
Pegaptanib Macugen Scorpion antivenom Anascorp
Peginterferon alfa-2a Pegasys (equine (Fab)¢2)
Peginterferon alfa-2b PEG-Intron Siltuximab Sylvant
Pembrolizumab Keytruda Sirolimus Generic, Rapamune
Pertuzumab Perjeta Tacrolimus (FK 506) Generic, Prograf, others
Pomalidomide Pomalyst Teriflunomide Aubagio
Ramucirumab Cyramza Thalidomide Thalomid
Ranibizumab Lucentis Tocilizumab Actemra
Raxibacumab ABthrax Trastuzumab Herceptin
Reslizumab Cinqair Ustekinumab Stelara
Rh o (D) immune globulin RhoGam, others Vedolizumab Entyvio
micro-dose
* Several drugs discussed in this chapter are available as orphan drugs but are not listed here. Other drugs not listed here will be found in other chapters (see Index).

REFERENCES Immunosuppressive Agents
General Immunology Capron A et al: Intra-cellular immunosuppressive drug monitoring: A step forward
towards better therapeutic efficacy after organ transplantation? Pharmacol
Levinson WE: Review of Medical Microbiology and Immunology, 13th ed. Res 2016;111:610.
McGraw-Hill, 2014. Choi WE, Reddy P: Current and emerging strategies for the prevention of graft-
Lubberts E: The IL-23–IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol versus-host disease. Nat Rev Clin Oncol 2014;11:536.
2015;11:415. Lee JH et al: A comprehensive review of the treatment of atopic eczema. Allergy
Murphy KM, Travers P, Walport M (editors): Janeway’s Immunobiology, 9th ed. Asthma Immunol Res 2016;8:181.
Garland Science, 2016. Sharma P, Scott DG: Optimizing methotrexate treatment in rheumatoid arthritis:
Sharma P, Allison JP: The future of immune checkpoint therapy. Science Prior to biologics. Drugs 2015;75:1953.
2015;348:56. Waldner M et al: New perspectives on mTOR inhibitors (rapamycin, rapalogs, and
TORKinibs) in transplantation. Br J Clin Pharmacol 2016;82:1158.
Hypersensitivity
Antilymphocyte Globulin & Monoclonal Antibodies
Borroni RG: Role of dermatology in pharmacogenomics: Drug-induced skin
injury. Pharmacogenomics 2015;16:401. Costa AG, Bilezikian JP: How long to treat with Denosumab. Curr Osteoporos
Rep 2015;13:415.
De Groot AC: New contact allergens: 2008 to 2015. Dermatitis 2015;26:199.
Cummings SR: Denosumab for prevention of fractures in postmenopausal women
with osteoporosis. N Engl J Med 2009;361:756.
Autoimmunity Spain L et al: Management of toxicities of immune checkpoint inhibitors. Cancer
Treat Rev 2013;44:51.
Aytan J: Use of biologics in SLE: A review of the evidence from a clinical perspec- Wolf M et al: Peripheral administration of antithymocyte globulins: A review of
tive. Rheumatology 2016;55:775 current literature. Transplant Rev (Orlando) 2013;27:17.
Cantini F et al: Tailored first-line biologic therapy in patient with rheumatoid
arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum Cytokines
2016;45:519.
Marzano AV et al: Immune-mediated inflammatory reactions and tumors as Akdis M et al: Interleukins (from IL-1 to IL-38), interferons, transforming growth
skin side effects of inflammatory bowel disease therapy. Autoimmunity factor β and TNF-α: Receptors, functions and roles in diseases. J Allergy
2014;47:146. Clin Immunol 2016;138:984.
Tiligada E et al: The expanding role of immunopharmacology: IUPHAR review 16.
Br J Pharmacol 2015;172:4217. Drug Allergy
Khan DA: Hypersensitivity and immunologic reactions to biologics: Opportuni-
Immunodeficiency Diseases ties for the allergist. Ann Allergy Asthma Immunol 2016;117:115.
Macy E: Practical management of patients with a history of immediate hypersensitivity
Sriaroon P, Ballow M: Immunoglobulin replacement therapy for primary immuno- to common non-beta-lactam drugs. Curr Allergy Asthma Rep 2016;16:4.
deficiency. Immunol Allergy Clin North Am 2015;35:713. Wickner PG, Hong D: Immediate drug hypersensitivity Curr Allergy Asthma Rep
2016;16:49.